16-week Open Randomized Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression: Pharmacogenomic and Biomarker Predictors of Response

Trial Profile

16-week Open Randomized Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression: Pharmacogenomic and Biomarker Predictors of Response

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Apr 2016

At a glance

  • Drugs Fluoxetine (Primary) ; Lamotrigine (Primary)
  • Indications Bipolar depression
  • Focus Therapeutic Use
  • Acronyms FLAME
  • Most Recent Events

    • 15 Apr 2016 Status changed from active, no longer recruiting to recruiting.
    • 15 Dec 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 15 Dec 2015 Study design changed from cross-over to parallel and minimum age of subjects included reduced from 85 to 65 years as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top